This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting (pre-reperfusion) and 3 months after reperfusion.
This study requires the consecutive enrollment of 60 patients at admission for first acute myocardial infarction. At enrollment, before reperfusion, a blood sample is obtained to measure B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting. This measure is then repeated at follow-up visit 3 months after reperfusion. The aim of the study is to identify specific subsets of patients and evaluate biomarkers variations.
Study Type
OBSERVATIONAL
Enrollment
16
measurement of BAFF and MGO levels before reperfusion and after 3 months
Istituto Clinico Città Studi
Milan, Italy
Identification of Inflammatory Biomarkers (BAFF) linked to ischemic event and outcome
elevation of BAFF levels
Time frame: Day 0
Identification of Glycation Biomarkers (MGO) linked to ischemic event and outcome
elevation of MGO levels
Time frame: Day 0
Identification of biomarkers variations (BAFF) complications and outcome
variation of BAFF from baseline
Time frame: After 3 months
Identification of biomarkers variations (MGO) complications and outcome
variation of MGO from baseline
Time frame: After 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.